Please assess the completion status of the following clinical trial:

Trial Title: Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 40 to 75 years on the day of inclusion~* Informed consent form has been signed and dated~* Able to attend all scheduled visits and to comply with all trial procedures~* For a woman of childbearing potential, use of an effective method of contraception or abstinence from at least 4 weeks prior to the first vaccination until at least 4 weeks after the last vaccination~* At risk for developing Clostridium difficile infection during the trial because of impending elective surgery or hospitalization within 60 days of enrollment, or current or impending residence in a long-term care facility or rehabilitation facility.~Exclusion Criteria:~* Known pregnancy, or a positive urine pregnancy test~* Currently breastfeeding a child~* Participation in another clinical trial investigating a vaccine, drug, medical device, or medical procedure in the 4 weeks preceding the first trial vaccination~* Planned participation in another clinical trial during the present trial period~* Receipt of any vaccine in the 4 weeks preceding the first trial vaccination, except for influenza (seasonal or pandemic) and pneumococcal vaccine~* Planned receipt of any vaccine in the 4 weeks following any trial vaccination, except for influenza (seasonal or pandemic) and pneumococcal vaccines~* Previous vaccination against Clostridium difficile with either the trial vaccine or another vaccine~* Current or prior Clostridium difficile infection (CDI) episode~* Receipt of blood or blood-derived products in the past 3 months, which might interfere with assessment of the immune response~* Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)~* Self-reported seropositivity for Human Immunodeficiency Virus (HIV), hepatitis B, or hepatitis C~* Anticipated or current receipt of kidney dialysis treatment~* Known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to a vaccine containing any of the same substances~* Self-reported thrombocytopenia, contraindicating intramuscular (IM) vaccination~* Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating IM vaccination~* Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily~* Current alcohol abuse or drug addiction that might interfere with the ability to comply with trial procedures~* Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with trial conduct or completion~* Identified as a study site employee who is involved in the protocol and may have direct access to trial-related data~* Subjects who have any history of intestinal diverticular bleeding~* Subjects who have had surgery within the past three months for gastrointestinal (GI) malignancy.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Group 1 (Type: EXPERIMENTAL): Participants will receive a dose Low-dose ACAM-CDIFF™ vaccine with adjuvant on Day 0, 7, and 30, respectively.
- Group 2 (Type: EXPERIMENTAL): Participants will receive a dose Low-dose ACAM-CDIFF™ vaccine without adjuvant on Day 0, 7, and 30, respectively.
- Group 3 (Type: EXPERIMENTAL): Participants will receive a dose High-dose ACAM-CDIFF™ vaccine with adjuvant on Day 0, 7, and 30, respectively.
- Group 4 (Type: EXPERIMENTAL): Participants will receive a dose High-dose ACAM-CDIFF™ vaccine without adjuvant on Day 0, 7, and 30, respectively.
- Group 5 (Type: PLACEBO_COMPARATOR): Participants will receive a dose Placebo (0.9% normal saline) on Day 0, 7, and 30, respectively.
- Group 6 (Type: EXPERIMENTAL): Participants will receive a dose of High-dose ACAM-CDIFF™ vaccine with adjuvant on Day 0, 7, and 180, respectively.
- Group 7 (Type: EXPERIMENTAL): Participants will receive a dose of High-dose ACAM-CDIFF™ vaccine with adjuvant on Day 0, 30, and 180, respectively.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete